Navigation Links
Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
Date:6/10/2013

NEW YORK, June 10, 2013 /PRNewswire/ -- Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York federal court.   That suit claimed that Royal Pharma's tender offer disclosures were inadequate.  As explained in Royalty Pharma's response to Elan's complaint, served on Elan just yesterday, Elan's claims were entirely without merit, and in any event were rendered irrelevant by the amended disclosures Royalty Pharma filed Friday, June 7.  Faced with the prospect of an embarrassing loss, Elan has chosen to walk away.  The voluntary withdrawal confirms that Royalty Pharma's disclosures have been full and accurate, and that investors have all the information they require to consider Royalty Pharma's highly compelling tender offer.

By voluntarily dismissing its claim today, Elan also avoids having to defend in open court its conduct with respect to the ADS record date.  Indeed, it was less than two hours after Royalty Pharma served discovery requests seeking to learn more information regarding Elan's board and senior management actions around the record date that Elan promptly dismissed its lawsuit.  Elan had also refused to allow Royalty Pharma to file publicly any of the emails or other documents it obtained from Elan in connection with its defense of Elan's lawsuit, or even to file Royalty Pharma's brief without redacting information from Elan's internal emails about the ADS record date.

Elan now claims the ADS record date has always been May 23, despite documentary proof that on May 22 and May 23, Elan's investor relations department told numerous investors the record date would be June 13.  Royalty Pharma believes that many investors have been deprived of their right to vote at the June 17 extraordinary general meeting as a result of Elan's actions relating to the record
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Royalty Rates Take Center Stage in Biopharma Dealmaking
2. Royalty Pharma Announces Proposal To Acquire Elan
3. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
4. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
5. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
6. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
7. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
8. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
9. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
10. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
11. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... quarter financial results on Tuesday, July 29, 2014, after the ... followed by a conference call with the investment community at ... be Robert A. Bradway , chairman and chief executive ... Live audio of the conference call will be simultaneously ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists who ... do to ensure that their practice will be a success. ... basic supplies they use the most can make all the ... dentists have recently discovered that purchasing discount dental supplies ... According to successful dentists across the ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
... 1, 2012 The FDA and representatives from the ... on proposed recommendations for the third reauthorization of a ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The recommendations would authorize the ... five years, plus adjustments for inflation. Details of the ...
... Corporation (NYSE: BSX ) announces first ... PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent ... the new device was performed by Professor Antonio ... at Columbus Hospital and San Raffaele Hospital in ...
Cached Medicine Technology:FDA and Industry Reach Agreement in Principle on Medical Device User Fees 2FDA and Industry Reach Agreement in Principle on Medical Device User Fees 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 4
(Date:7/25/2014)... 25, 2014 Health Advocate™, Inc., the ... subsidiary of West Corporation, is introducing its newest solution ... Costs and Enhance Quality. , The webinar will be ... ET and again at 2 PM ET. For more ... http://www.HealthAdvocate.com/Analytics or call 866.799.2655. , In an ...
(Date:7/25/2014)... could be treated more quickly after Manchester research ... and blood test on arrival, is effective in ... new study shows., The findings of a research ... Journal, could potentially make a huge difference to ... the most common reason for emergency hospital admission. ...
(Date:7/25/2014)... A probiotic that prevents obesity could be on ... in the gut inhibit weight gain, insulin resistance ... in mice, Vanderbilt University investigators have discovered. , ... to human," said senior investigator Sean Davies, Ph.D., ... most of the negative consequences of obesity in ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
(Date:7/25/2014)... -- Dietary changes can dramatically alter the balance of ... to a new study. These fluctuations could ... ease flare-ups for people with certain chronic illnesses, such ... the researchers said. Trillions of bacteria live in ... isn,t well understood, the Massachusetts Institute of Technology (MIT) ...
Breaking Medicine News(10 mins):Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... 2.1 Million Teens ... ... 2009 -- With an estimated 2,500 children ages 12 to 17 taking a prescription painkiller ... with MedSafe, the developers of a state-of-the-art medication lock-box, to curb the problem where it ...
... worker study suggests more potential hazards from the plastics ... to high levels of the controversial plastics chemical bisphenol ... including impotence and low sex drive, among Chinese factory ... researchers stressed that the workers were exposed to BPA ...
... ... is the inspiration for a new film which will find its way onto the ... ... event, the Molecular Medicine Tri-Conference (February 3-5, 2010) will feature inspirational Keynote John F. ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... LONDON, November 11 Extensive research conducted ... University of,Sheffield on the Simbionix PROcedure Rehearsal Studio(TM), was ... 2009 congress in Lisbon, Portugal. , ... year, is,the world,s first patient specific system to enable ...
... ... home or office using methods and products that are government-approved, but that won,t harm your ... Rhinebeck, ... The Natural Flu Protection Kit, the first product to emerge from the company’s partnership with ...
Cached Medicine News:Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 2Health News:D.A.R.E Partners with MedSafe to Tackle Teen Prescription and Over the Counter Drug Abuse at Home 3Health News:BPA Tied to Impotence in Men 2Health News:BPA Tied to Impotence in Men 3Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: